



Notice of Action

Date: March 05, 2021 **Study Number:** IRB-1991-0002
Meeting Date: Expedited Review 45 CFR 46.110 Minor Changes in Previously Approved Research
Principal Investigator: Stephen Spellman
Study Title: *Protocol for a Research Sample Repository for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries*
Protocol Version: May 2019 Version 12.0
Number of participants approved: Unlimited

TYPE OF REVIEW:

AMENDMENT. Documents reviewed are listed below:

- Study 0002 COVID Vaccine Repository RECIPIENT Adult Parent Consent_v2.0.docx (Consent Form)
- Study 0002 COVID Vaccine Repository RECIPIENT Minor Assent 12-17_v2.0.docx (Consent Form)
- Study 0002 COVID Vaccine Repository RECIPIENT Minor Assent 7-11_v2.0.docx (Consent Form)

STATUS:

APPROVED

Stipulations have been met. Study may be initiated/continued.

Amendment Approved as of: March 01, 2021

- All projects must be reviewed for continuation of work. No modification may be made in the protocol or in the wording of the IRB approved consent(s) without the prior approval of the IRB.
- For donors not covered by the NMDP IRB, additional IRB approval from participating donor centers will be required.
- Donor/recipient consent forms are attached, if applicable.
- The Principal Investigator is responsible for reviewing the information in the email that accompanies this Notice of Action.

Reconsent (if applicable): The NMDP IRB determined that re-consent of study subjects is NOT required. Consent with this amendment is only required if peri-vaccination blood samples will be collected and as such is prospective. Retrospective re-consent is not necessary.

Authorized signature:

Electronically signed by Brian Lindberg, J.D. on 03/08/2021 8:31 AM ET